Skip to main content
. 2024 Oct 23;11(6):e200328. doi: 10.1212/NXI.0000000000200328

Figure 3. Characteristics of 3 Women Who Used Ocrelizumab (OCR) Before Conception and Experienced Postpartum Relapse.

Figure 3

OCR use during pregnancy was based on the last administered dose. ARR = annualized relapse rate; EDSS = Expanded Disability Status Scale.